Mesoblast's first-rate clinical results along with its strategic alliance with Cephalon, underscores its position as the world's leading stem cell and regenerative medicine company. Silviu served as Executive Director at Mesoblast. Silviu Itescu has a Medical Degree from Monash University and a Specialty Training in Internal Medicine and Immunology/Rheumatology from New York University. Research output per year. Do you need to know more about Silviu Itescu? Dive into details by clicking on the dots. Dr Itescu acquired worldwide license in 2004 to commercialize orthopedic applications of proprietary adult stem cell technology that was developed by scientists at South Australia's Hanson Institute and Institute of Medical and Veterinary Science and formed a company called Mesoblast by raising funds through IPO at Australian Securities Exchange. Dr Itescu, who is a member of the US President's Council on Bioethics and the US Food and Drug Administration's Biological Response Modifiers Advisory Committee on cell therapy, has guided Mesoblast's growth.
Learn more about Biotechnology. ", With the strong backing from his family, core investors, the medical community and support of a key group of executives, Mesoblast has been able to sail smoothly. 15 March 2012 | Influencers | By BioSpectrum Bureau, Dr Silviu Itescu: Pioneer of adult stem cell therapies.
Chief Financial Officer. "We expect successful launch of our products globally within the next few years," concludes Dr Itescu. Chief Executive Officer and Managing Director -.
The firm, is increasing the numbers of its new strategic domestic and international institutional investors, and has a growing number of commercial opportunities.
National Health & Medical Research Council (NHMRC), Research output: Contribution to journal › Article › Research › peer-review. My extensive work in cardiac transplantation only served to further underline the lack of sufficient meaningful therapies," says Dr Itescu. BioSpectrum recognized his efforts and awarded him with the BioSpectrum Asia Pacific Bioscience Industry Person of the Year Award for 2011.
", While speaking about the growth of the company and the changing regulatory scenario, Dr Itescu says, "The current challenges for Mesoblast are in executing our late stage clinical programs, to demonstrate that we can use our resources and cash wisely to broaden our product pipeline and to successfully build an international team as part of a global biopharmaceutical company.
Dr. Silviu Itescu has served on the Mesoblast board since the Company’s founding in 2004, was executive director from 2007 and became CEO and managing director in 2011.Prior to founding Mesoblast in 2004, he established an international reputation as a physician-scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation and heart failure. 9,226 executive movements have been recorded in the last 12 months. Julien Ng, Dr. Recent external collaboration on country level.
View the executives' biographies.
We will get in touch with you shortly.
Recently, it announced outstanding clinical trial results of its stem cell product, Revascor, in patients with congestive heart failure, an application with multi-billion dollar revenue potential. Driven by the fascination towards stem cell research, Dr Itescu began to look for more effective ways of restoring damaged tissue, particularly the heart.
Obviously persistence, diligence, focus, setting priorities and goals, and retaining an executive group of people; provide the expertise and complementary skills to de-risk outcomes.". Commenting on this, Dr Itescu says, "I was intrigued by biology and I had a strong desire to make a substantial contribution and to help those in need. Mesoblast has unlocked significant value from its proprietary platform technology and has identified many commercial opportunities and markets. Add private notes. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. Overview; Network; Projects (1) Research Output (25) If you made any changes in Pure these will be visible here soon. 1 North Bridge Road,#08-08 High Street Centre, Singapore 179094Tel : +65-63369142Fax : +65-63369145, © 2020 MM Activ Sci-Tech Communications. Here are a few. Silviu Itescu – MBBS, FRACP Chief Executive Officer (Executive Director) Dr Itescu has served on the Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. Select key words to follow your clients.
Prior. In the Biotechnology industry, Silviu Itescu has 17,293 colleagues in 1,472 companies located in 42 countries. 11/509,002 filed Aug. Know his bio, wiki, net worth, salary, age, married life with wife, Samantha, and son. A Quinquagenarian from Australia, Dr Silviu Itescu, is based out of the US and has been traveling tirelessly between New York and Melbourne with the sole objective of rapid development and commercialization of therapies to treat patients with bone and joint diseases. The strength of its results underpinned Mesoblast's ability to successfully enter into a major strategic alliance with global biopharmaceutical company, Cephalon, in December 2010. All rights reserved | Disclaimer, Web Interface Conceived and Powered By : SCI Knowledge Interlinks. Download our data in Excel on your PC.
Thanks for contacting us! He was the first person who proved that certain adult stem cells from bone marrow could be used to repair damaged hearts by creating new small capillary vascular networks.
Report an error After three unsuccessful trials, for your security.
Following this, he relocated to the US for nearly 20 years with the desire to broaden his knowledge base and also to expose himself to different cultures and complementary expertise.
While working as the head of Transplantation Immunology at Columbia University Medical Center, US, Dr Itescu specialized in the field of immunosuppressant to prevent the rejection of transplanted organs. Contact the executives through our email platform.
At Mesoblast, Silviu Itescu has 14 colleagues who can be contacted including Donal O'Dwyer (Director), Michael Spooner (Director)… Industry Colleagues. Melbourne-based Mesoblast and its subsidiary Angioblast, based in New York, have been working on commercializing adult stem cell-based products for large clinical indications with unmet clinical needs that present long-term sustainable market opportunities. By continuing you agree to the use of cookies.
Silviu Itescu. "My area of clinical focus was cardiovascular medicine and the major unmet needs in patients with advanced heart failure and the lack of alternatives available to them.
File your clients in folders. At Mesoblast, Silviu Itescu has 14 colleagues who can be contacted including Donal O'Dwyer (Director), Michael Spooner (Director)…. The company's core strategy is based on three focus areas: products to treat cardiovascular and neurodegenerative diseases; intravenously-delivered products to treat a wide range of inflammatory and immune-based conditions including diabetes, lung diseases, and joint diseases; and the company's suite of orthopedic products for repair of bone and cartilage tissues.
Network Recent external collaboration on country level. Learn about your clients' org charts. Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2020 Elsevier B.V. We use cookies to help provide and enhance our service and tailor content. Novel therapeutic strategies to reduce the burden of chronic heart failure. In the Biotechnology industry, Silviu Itescu has 17,497 colleagues in 1,486 companies located in 42 countries. PROFESSOR, Hudson Institute - The Ritchie Centre; Email silviu.itescu@hudson.org.au; 2004 2017. For each of our 909,910 listed executives. Professor.
Karen Edward is affiliated with Mesoblast, Inc. Stay informed and up-to-date on your network with RelSci news and business alerting service.
Silviu was Director at Diversa, and Director at Zenyth Therapeutics. ID:334008, Immunoselected STRO-3+ mesenchymal precursor cells reduce inflammation and improve clinical outcomes in a large animal model of monoarthritis, Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: A controlled double-blind randomised trial, Optimization of alginate purification using polyvinylidene difluoride membrane filtration: Effects on immunogenicity and biocompatibility of three-dimensional alginate scaffolds, Reconstitution of degenerated ovine lumbar discs by STRO-3-positive allogeneic mesenchymal precursor cells combined with pentosan polysulfate, A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure.
Use our Premium/VIP Service to contact Silviu Itescu by email now.
Dr Itescu, who was born in Romania, studied in Australia from the age of seven until he completed his masters in medicine at the University of Melbourne.